<DOC>
	<DOCNO>NCT00213005</DOCNO>
	<brief_summary>The study objectives assess mucosal safety Carraguard® gel apply vaginally per day 14 day sexually abstinent sexually active , HIV-positive woman ; evaluate effect Carraguard® gel vaginal flora woman ; evaluate effect Carraguard® gel shed HIV-1 genital tract woman ; evaluate safety Carraguard® gel apply directly penis per day 7 day sexually abstinent , HIV-positive men ; ass whether symptom report female male participant study may relate use Carraguard® gel ; examine dimension acceptability , compliance , study placebo product .</brief_summary>
	<brief_title>Safety Acceptability Carraguard® HIV Positive Women Men</brief_title>
	<detailed_description>We propose safety study Council ’ lead candidate microbicide , Carraguard® three cohort Durban , South Africa : sexually abstinent HIV-positive woman , sexually abstinent HIV-positive men , sexually active HIV-positive woman . Sexually active woman must HIV-positive seroconcordant relationship ( confirm HIV test woman male partner ) write informed consent obtain male partner . Women men cohort randomize one three study group : Carraguard® gel , match placebo methyl-cellulose gel , product . The main objective study investigate change vulvar , vaginal , cervical epithelium , vaginal flora , HIV-1 shed genital tract female participant , change penile skin epithelium male participant . We also evaluate symptom report participant , several dimension acceptability compliance study placebo gel . Reactions non-contraceptive microbicide assess , well reason voluntary discontinuation non-use Carraguard® placebo ( determine review daily diary ) record . Exit focus group discussion hold male female participant discuss aspect acceptability compliance . Self-reported symptom also investigate clinical examination need study endpoint include genital itching burning , frequent urination , burn urinating , genital pain , pain sex , abnormal vaginal penile discharge .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<criteria>Positive HIV1 license HIV test ( confirmation ) agree inform test result Age 18 45 year old , woman ( maximum age men ) In good health , define CD4+ cell count &gt; 200 x 106/L current absence opportunistic infection may interfere protocol adherence If treatment HIV infection ( include immuneboosters Moducare vitamin ) : treatment stay constant duration study For sexually abstinent cohort : Willing abstain sexual intercourse masturbation duration study ( 3 week ) 48 hour join study For sexually active cohort : Willing sex one male partner , male partner willing sex participant , duration study Regular menstrual cycle ( 35 week period ) amenorrheic due longterm ( three month ) DMPA use ( DMPArelated side effect could interfere study participation last 6 month ) Planning live Durban next 6 month Willing refrain use vaginal product duration study ( 3 week ) , include spermicide , diaphragm/cervical cap , traditional dry tighten agent , douche , tampon , medicinal product Willing able comply aspect study protocol , include clinical evaluation study gel administration ( applicable ) Willing able give inform consent . Currently pregnant , menopausal lactating , desire become pregnant time study participation Current recent participation ( within past 30 day ) clinical trial , include trial HIV therapeutic trial vaginal product ( include ongoing study Department Paediatrics King Edward VIII Hospital ) Delivery , miscarriage abortion within last six week Gynecological surgery instrumentation last three month History nonmenstrual vaginal bleeding intercourse last month Presence clinically detectable genital abnormality ( i.e . vulvar , vaginal , cervical and/or perianal ulcer and/or lesion ) epithelium currently disrupt likely disrupt ( e.g . herpes blister ) . Women healed/driedup lesion past infection , lesion epithelium currently intact unlikely disrupt , eligible enrollment . Presence sexually transmit infection ( STI ) , symptomatic yeast infection , bacterial vaginosis ( BV ) , diagnose clinical exam laboratory test screen . Women asymptomatic yeast infection BV may enrol . Abnormal Pap smear ( CIN I high ) screen Use spermicide spermicidally lubricate condom within week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>Microbicides</keyword>
	<keyword>HIV prevention</keyword>
	<keyword>HIV positive</keyword>
	<keyword>carrageenan</keyword>
	<keyword>safety trial</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>HIV</keyword>
</DOC>